A number of other brokerages have also recently commented on BYSI. HC Wainwright restated a buy rating and issued a $50.00 price target on shares of BeyondSpring in a research report on Monday, August 21st. Zacks Investment Research cut BeyondSpring from a hold rating to a sell rating in a research report on Monday, November 13th.
Shares of BeyondSpring (BYSI) traded up $0.06 on Thursday, reaching $32.57. The company’s stock had a trading volume of 43 shares, compared to its average volume of 1,300. BeyondSpring has a fifty-two week low of $16.55 and a fifty-two week high of $48.49.
An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for approximately 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring at the end of the most recent reporting period. 1.22% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Maxim Group Analysts Give BeyondSpring (BYSI) a $52.00 Price Target” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/12/03/maxim-group-analysts-give-beyondspring-bysi-a-52-00-price-target.html.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
What are top analysts saying about BeyondSpring Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BeyondSpring Inc. and related companies.